The CEO of NRx – the US company in charge of trials of Israel’s BriLife coronavirus vaccine – said NRx is designing a Phase II study of BriLife as a booster to protect against COVID-19 variants. The study will be led by the research heads of Israel’s Hadassah and Sourasky (Ichilov) hospitals.
https://www.jns.org/israel-aims-to-test-brilife-vaccine-candidate-as-booster-dose/